AtriCure (ATRC) Chief Scientific Officer sells 5,000 shares at $29.83

Rhea-AI Filing Summary

AtriCure, Inc. Chief Scientific Officer Doraiswamy Vinayak reported an open-market sale of 5,000 shares of common stock. The shares were sold at a weighted average price of $29.83 per share, in multiple trades executed between $29.79 and $29.92. Following this transaction, he directly holds 96,875 shares of AtriCure common stock.

Insider Trade Summary

Net Seller: 5,000 shares

Net Sell 1 txn

Insider Doraiswamy Vinayak

Role Chief Scientific Officer

Sold 5,000 shs ($149K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,000	$29.83	$149K

Holdings After Transaction: Common Stock — 96,875 shares (Direct)

Footnotes (1)

1. F1. This transaction was executed in multiple trades at prices ranging from $29.79 to $29.92 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/16/2026 - 08:14 AM Learn about SEC filing dates

FAQ

What insider transaction did AtriCure (ATRC) report for Doraiswamy Vinayak?

AtriCure reported that Chief Scientific Officer Doraiswamy Vinayak sold 5,000 shares of common stock. The transaction was an open-market sale, disclosed on a Form 4 insider filing, and reflects a routine change in his direct holdings.

At what price did the AtriCure (ATRC) Chief Scientific Officer sell shares?

The 5,000 AtriCure shares were sold at a weighted average price of $29.83 per share. The trade was executed in multiple transactions, with prices ranging from $29.79 to $29.92, as disclosed in the Form 4 footnote.

How many AtriCure (ATRC) shares does Doraiswamy Vinayak hold after the sale?

After the reported sale, Doraiswamy Vinayak directly holds 96,875 shares of AtriCure common stock. This post-transaction balance reflects his remaining direct ownership as shown in the Form 4 insider filing for the reported transaction.

What type of insider transaction was reported for AtriCure (ATRC)?

The Form 4 shows an open-market sale of common stock by AtriCure’s Chief Scientific Officer. It is classified with transaction code “S,” indicating a sale in an open market or private transaction, rather than an option exercise, gift, or tax withholding.

Did the AtriCure (ATRC) Form 4 mention how the sale was executed?

Yes. The Form 4 footnote states the transaction was executed in multiple trades. Sale prices ranged from $29.79 to $29.92 per share, and the reported $29.83 figure represents the weighted average sales price across those trades.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doraiswamy Vinayak

(Last) (First) (Middle)

7555 INNOVATION WAY

(Street)

MASON OH 45040-9695

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/12/2026		S		5,000	D	$29.83(1)	96,875	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $29.79 to $29.92 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ Vinayak S. Doraiswamy	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.